Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936052 | 0.87 | HTR2A (0.41) | CHRM4CARM1PRMT6HTR2ASLC6A4 | |
| SCHEMBL26697782 | 0.81 | EGLN2 (0.36) | CHRM4ENPP1MBOAT4LMNA | |
| SCHEMBL31052765 | 0.78 | EGLN2 (0.42) | ENPP1LMNA | |
| SCHEMBL26892701 | 0.78 | EGLN2 (0.42) | ENPP1LMNA | |
| SCHEMBL17653849 | 0.72 | EPHX2 (0.52) | L3MBTL1LMNAHTTSMN1; SMN2EPHX2 | |
| SCHEMBL26697752 | 0.69 | EGLN2 (0.38) | CHRM4LMNASMN1; SMN2 | |
| SCHEMBL29936085 | 0.69 | EGLN2 (0.38) | CHRM4LMNASMN1; SMN2 | |
| SCHEMBL27093496 | 0.68 | KDM4E (0.36) | HTR2ASLC6A4LMNA | |
| SCHEMBL26697649 | 0.65 | ALDH1A1 (0.43) | LMNAHTT | |
| SCHEMBL1033641 | 0.64 | LMNA (0.61) | LMNAHTTSMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4323356-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | Nuvalent, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2022221227-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2022-10-20 | — | — | WO | disclosed |